Revenue - Additional Information (Detail) - USD ($)		3 Months Ended			9 Months Ended		12 Months Ended
	May 17, 2024	Dec. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Revenue			$ 10,524,000	$ 15,202,000	$ 31,685,000	$ 31,990,000
ANI Pharmaceuticals, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Product rights agreement, closing date					May 17, 2023
Receipt of upfront license fee					$ 75,000,000
Eyebiotech License Agreement [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment	$ 500,000
Receipt of upfront license fee					500,000
RPA [Member] | SWK [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment					16,500,000
Revenue			300,000	300,000	900,000	700,000
Deferred revenue, current			1,700,000		1,700,000				$ 1,400,000
Deferred revenue, non-current			11,200,000		11,200,000				$ 12,400,000
YUTIQ [Member]
Disaggregation Of Revenue [Line Items]
Revenue			700,000	800,000	2,400,000	13,400,000
Product [Member]
Disaggregation Of Revenue [Line Items]
Revenue			664,000	816,000	2,390,000	13,483,000
Product [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue			0	0	500,000	500,000
Product [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue			700,000	1,000,000	1,900,000	1,200,000
License and Collaboration Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue			9,561,000	14,137,000	27,906,000	17,768,000
License and Collaboration Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Revenue			200,000	400,000	500,000	800,000
License and Collaboration Agreement [Member] | Eyebiotech License Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue					500,000
Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Revenue			299,000	249,000	1,389,000	739,000
Royalty Income [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue			0	0	500,000	0
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment					75,000,000
Deferred revenue, current			24,300,000		24,300,000
Deferred revenue, non-current			0		$ 0
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Guaranteed payments		$ 1,875,000						$ 7,500,000
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Maximum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period					2028
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Maximum [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Royalty payments							$ 70,000,000
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Minimum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period					2025
Product Rights Agreement [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue			$ 9,400,000	$ 13,600,000	$ 26,800,000	$ 16,800,000
Supply Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Initial term of the supply agreement					2 years
Initial Term of Estimated Supply Units					2 years